By Hannah Green and Greg Ryan Gov. Maura Healey has laid out her plans to reauthorize the Life Sciences Initiative with a new $1 billion, 10-year strategy, as well as put an additional $1 billion toward making the Bay State a hub for the clean energy industry. The so-called “Life Sciences 3.0,” as well as a package of […]
By: Emily Fu North River Leerink (NRL) has announced that 100 Chestnut, a purpose-built 200,000 square feet life Science building in Somerville, MA, is 90% leased. Ultragenyx, relocating from Kendall Square, has leased 42,500 square feet to consolidate their east coast R&D. CRADL has leased 16,000 square feet to open a contract vivarium and in […]
By Hannah Green A Framingham-based biotech is relocating its headquarters to a new space closer to the center of Massachusetts’ biotech industry. BPGbio announced on Wednesday it was moving into 70,000 square feet of lab and office space at 300 Third Avenue in Waltham. The biotech company plans to move into two full floors of the […]
By Richard Berger There are early signs of recovery within the life sciences environment following a recent investment slowdown as venture capital is re-emerging, tenants are coming off the sidelines and average deal sizes are hitting all-time highs, according to a recent report from Cushman & Wakefield. Its research manager, Sandy Romero, said venture capital […]
BY REENA KARASIN Greentown Labs’ 200+ startups are developing, deploying, and commercializing climatetech solutions to decarbonize the key greenhouse-gas-emitting sectors—agriculture, buildings, electricity, manufacturing, and transportation—and build resilient communities. There’s an incredible amount of work and collaboration needed to get these technologies out of the lab and into the world, from early-stage funding, to pilot projects, to first commercial […]
By Rowan Walrath In a first for the Nobel Prize-winning gene-editing technology, a CRISPR-based drug has been approved in the U.S. The Food and Drug Administration gave the green light Friday to exa-cel, a drug made by two Boston-based companies, Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) and CRISPR Therapeutics Inc. (Nasdaq: CRSP). It will be marketed under […]
By Rowan Walrath Somerville’s bluebird bio Inc. has won its third U.S. drug approval since splitting into two companies. On Friday, the Food and Drug Administration approved lovo-cel, a gene therapy for sickle-cell disease. The drug will be marketed under the name Lyfgenia. The FDA announced Lyfgenia’s approval at the same time it said it had approved […]
By Greg Ryan One year ago almost to the day, the Nissenbaum family was on the brink of becoming $150 million richer. Things did not go as planned. For much of 2022, the Nissenbaums had a tentative deal in place to sell their car-parts junkyard near Somerville’s Union Square to the real estate developers building the […]
By Charlotte LoBuono The Massachusetts Biotechnology Council, the nation’s oldest biotech trade association, released its 2023 Industry Snapshot on September 6. The report found that biotech and pharmaceutical companies in Massachusetts added more research and development and biomanufacturing jobs than in most other states in 2022. The biopharma R&D workforce in Massachusetts had a year-over-year growth rate of 8.5% […]
By Rowan Walrath A consortium of leaders in the private and public sectors are making a push for Massachusetts to play host to a hub of a new, biomedical research-focused federal agency. ARPA-H, short for the Advanced Research Projects Agency for Health, is tasked with kickstarting biomedical innovation. While its home base will be in the […]
